In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). (Q38979373)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

author name string

Aya Kikuchi

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Takashi Furutani

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Hidenori Azami

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Kazushi Watanabe

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Tatsuya Niimi

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Yoshiteru Kamiyama

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sadao Kuromitsu

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Edwina Baskin-Bey

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Marten Heeringa

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Taoufik Ouatas

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Kentaro Enjo

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

1 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

860-870

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Adaptation or selection--mechanisms of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Blockade of testicular and adrenal androgens in prostate cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

AKR1C3 as a target in castrate resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Structure and activity of the murine type 5 17beta-hydroxysteroid dehydrogenase gene(1).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0130-5

21 January 2018

Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retention of NADPH-linked quinone reductase activity in an aldo-keto reductase following mutation of the catalytic tyrosine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase

1 reference

https://pubmed.ncbi.nlm.nih.gov/24981575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0130-5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dimensions Publication ID

0 references

release_t2tpo5fsovaxjigc6ctmr77w5e

1 reference

https://api.fatcat.wiki/v0/release/t2tpo5fsovaxjigc6ctmr77w5e

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38979373&oldid=2227617391"